The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
what matters now is the phase three trial which is ongoing and that's testing the the more important question which is does eliminating LP little a via this mechanism reduce clinical events does it reduce major adverse cardiac events so the answer to that question will determine whether or not this drug is approved and therefore becomes available
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
What matters now is the phase three trial which is ongoing and that's testing the the more important question which is does eliminating LP little a via this mechanism reduce clinical events does it reduce major adverse cardiac events